Context Therapeutics (NASDAQ:CNTX) Now Covered by William Blair

William Blair started coverage on shares of Context Therapeutics (NASDAQ:CNTX - Get Free Report) in a research note issued to investors on Monday, MarketBeat reports. The brokerage set an "outperform" rating on the stock. William Blair also issued estimates for Context Therapeutics' Q1 2025 earnings at ($0.05) EPS, Q2 2025 earnings at ($0.06) EPS, Q3 2025 earnings at ($0.07) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.31) EPS, FY2027 earnings at ($0.40) EPS and FY2028 earnings at ($0.55) EPS.

Several other equities research analysts have also recently issued reports on the company. JMP Securities started coverage on Context Therapeutics in a report on Wednesday, January 8th. They set an "outperform" rating and a $4.00 price objective on the stock. Citizens Jmp raised shares of Context Therapeutics to a "strong-buy" rating in a research note on Wednesday, January 8th. D. Boral Capital reissued a "buy" rating and issued a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a report on Friday, March 21st. Seven analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $6.17.

Context Therapeutics Stock Up 6.0 %

Shares of CNTX traded up $0.06 during trading hours on Monday, reaching $1.00. 365,881 shares of the company traded hands, compared to its average volume of 409,185. The stock has a market capitalization of $89.70 million, a PE ratio of -1.10 and a beta of 2.18. The stock has a fifty day simple moving average of $0.77 and a 200 day simple moving average of $1.22. Context Therapeutics has a fifty-two week low of $0.55 and a fifty-two week high of $2.75.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last released its quarterly earnings results on Thursday, March 20th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.01. Research analysts predict that Context Therapeutics will post -0.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Hedge funds have recently made changes to their positions in the business. Jane Street Group LLC acquired a new stake in Context Therapeutics in the 4th quarter valued at $29,000. Citadel Advisors LLC acquired a new stake in shares of Context Therapeutics in the fourth quarter valued at about $31,000. Shay Capital LLC purchased a new stake in shares of Context Therapeutics during the 4th quarter valued at about $52,000. Clear Harbor Asset Management LLC lifted its position in Context Therapeutics by 60.6% during the 4th quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock worth $61,000 after acquiring an additional 21,804 shares in the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in Context Therapeutics in the 4th quarter worth approximately $94,000. Hedge funds and other institutional investors own 14.03% of the company's stock.

Context Therapeutics Company Profile

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.